Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (2)

2022

  1. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study

    Journal of Headache and Pain, Vol. 23, Núm. 1

2021

  1. Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm

    Advances in Therapy, Vol. 38, Núm. 8, pp. 4442-4460